Five patients remained on the 60-mg starting dose of cobimetinib. The dosage was reduced to 40 mg for 8 patients, and 2 patients had a reduced dosage to 20 mg.
“The safety and tolerability have been similar to other studies of cobimetinib,” Diamond said. “One patient was removed for toxicity, but none for intolerable side effects. The optimal duration and dosing of cobimetinib remain unknown.”
Diamond EL, Durham BH, Dogan A, et al. Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders. In: Proceedings from the 59th ASH Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 257.